Skip to main content

Macular Dystrophy, North Carolina

OMIM ID:

autosomal dominant

Macular Dystrophy, North Carolina

Alternate Names

NCMD
MCDR1
central areolar pigment epithelial dystrophy
CAPED
central pigment epithelial and choroidal degeneration
central foveal dystrophy

Defective Genes

6q14-q16.2 locus

Clinical Characteristics

Ocular Features

North Carolina macular dystrophy is characterized by central macular defects that are present at birth but rarely progress. The fundus findings are highly variable and are usually more dramatic than expected from the visual acuity, which ranges from 20/40 to 20/200, with an average around 20/50. The clinical findings have been classified into different grades: In Grade I, fine drusen-like lesions at the level of the retinal pigmented epithelium are found in the central macular area. Grade II exhibits central confluent drusen with or without pigmentary changes, retinal pigment epithelium atrophy, disciform scar formation or neovascularization. Grade III is characterized by a well-delineated chorioretinal degeneration with hyperpigmentation at the border of the lesion. A central crater-like lesion that affects all retinal layers, as well as the deep choroidal tissue, is a typical finding. It is surrounded by an elevated ridge, which is 3-4 disc diameters size.  Color vision and electrophysiological testing are usually normal.

Some patients have choroidal neovascularization that may be responsive to anti-vascular endothelial growth factor treatment. 

Although first described in a 4 generation North Carolina family, it has since been found in a variety of ethnic groups and geographic locations.

Systemic Features

No general systemic manifestations are associated with North Carolina macular dystrophy.

Genetics

Inheritance

North Carolina macular dystrophy is an autosomal dominant disorder with high penetration.  One locus for the disorder, designated MCDR1 and containing a DNase 1 hypersensitivity site, has been mapped to 6q14-q16.2 and adversely impacts the retinal transcription factor gene PRDM13.  Multiple variants in this area have been identified.  However, other forms including MCDR2 (608051) resulting from mutations in PROM1 (4p15) and MCDR3 (608850) (linked to a locus at 5p13-p15) have been reported. 

The disorder was initially described in a family of Irish descent in North Carolina, and affected individuals have been identified in European, Asian and South American families as well.

Pedigree

Autosomal dominant

Autosomal dominant disorders require only one mutation for the disease to be expressed.  Since an affected parent has two chromosomes, only one of which has the mutant gene, parents can expect that half (50%) of their children will receive that one and inherit the disease.  It is common for individuals that inherit the mutation, however, to not have evidence of the disease (nonpenetrance).

Image
Sample pedigree of autosomal dominant inheritance

Autosomal dominant inheritance leads to a vertical pattern of transmission

Treatment & Management

For patients with choroidal neovascularization, standard treatment for neovascularization may be used. Low vision aids can be useful for other forms of the disorder with decreased visual acuity.

Selected Resources

Web Resources

Publications

Displaying 1 - 6 of 6

A Reappraisal of the Clinical Spectrum of North Carolina Macular Dystrophy

PubMedID: 19616854

CHOROIDAL NEOVASCULARIZATION IN NORTH CAROLINA MACULAR DYSTROPHY RESPONSIVE TO ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

PubMedID: 30383557

Clinical characterization and genetic mapping of North Carolina macular dystrophy

PubMedID: 17976682

Hereditary Macular Degeneration and Amino-Aciduria

PubMedID: 5100467

North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13

PubMedID: 26507665

North Carolina Macular Dystrophy, Revisited

PubMedID: 2622620